Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China; Department of Molecular Cell Biology, Cancer Genomics Centre and Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Trends Biochem Sci. 2013 Dec;38(12):612-20. doi: 10.1016/j.tibs.2013.10.001. Epub 2013 Nov 14.
The transforming growth factor (TGF)-β and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathways are used in cells to control numerous responses, including proliferation, apoptosis, and migration. TGF-β is known for its cytostatic effects in premalignant states and its pro-oncogenic activity in advanced cancers. The pro-cell survival response exerted by growth-factor-mediated activation of PI3K/AKT has been linked to stimulation of tumor formation. Both TGF-β receptor and PI3K/AKT pathways were initially modeled as linear signaling conduits. Although early studies suggested that these two pathways might counteract each other in balancing cell survival, emerging evidence has uncovered multiple modes of intricate signal integration and obligate collaboration in driving cancer progression. These new insights provide the rationale for exploring their dual targeting in cancer.
转化生长因子 (TGF)-β 和磷脂酰肌醇 3-激酶/蛋白激酶 B (PI3K/AKT) 信号通路在细胞中用于控制多种反应,包括增殖、凋亡和迁移。TGF-β 以其在癌前状态下的细胞静止作用和在晚期癌症中的促癌作用而闻名。生长因子介导的 PI3K/AKT 激活所产生的促细胞存活反应与肿瘤形成的刺激有关。TGF-β 受体和 PI3K/AKT 途径最初被建模为线性信号传导途径。尽管早期研究表明这两种途径可能在平衡细胞存活方面相互拮抗,但新出现的证据揭示了复杂信号整合的多种模式和在推动癌症进展方面的强制性协作。这些新的见解为探索它们在癌症中的双重靶向提供了依据。